- Home
- GENK vs LEXX Comparison
GENK vs LEXX Comparison
Compare GENK & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- LEXX
- Stock Information
- Founded
- GENK 2011
- LEXX 2004
- Country
- GENK United States
- LEXX Canada
- Employees
- GENK N/A
- LEXX N/A
- Industry
- GENK Restaurants
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- LEXX Health Care
- Exchange
- GENK Nasdaq
- LEXX Nasdaq
- Market Cap
- GENK 36.5M
- LEXX 39.1M
- IPO Year
- GENK 2023
- LEXX N/A
- Fundamental
- Price
- GENK $6.87
- LEXX $1.98
- Analyst Decision
- GENK Strong Buy
- LEXX Strong Buy
- Analyst Count
- GENK 3
- LEXX 2
- Target Price
- GENK $13.17
- LEXX $11.00
- AVG Volume (30 Days)
- GENK 54.5K
- LEXX 245.8K
- Earning Date
- GENK 03-05-2025
- LEXX 01-10-2025
- Dividend Yield
- GENK N/A
- LEXX N/A
- EPS Growth
- GENK 483.78
- LEXX N/A
- EPS
- GENK 0.17
- LEXX N/A
- Revenue
- GENK $198,834,000.00
- LEXX $496,923.00
- Revenue This Year
- GENK $14.66
- LEXX $20.39
- Revenue Next Year
- GENK $21.47
- LEXX $113.25
- P/E Ratio
- GENK $41.10
- LEXX N/A
- Revenue Growth
- GENK 12.50
- LEXX 77.63
- 52 Week Low
- GENK $5.61
- LEXX $1.36
- 52 Week High
- GENK $14.46
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- GENK 34.31
- LEXX 40.43
- Support Level
- GENK $7.11
- LEXX $1.87
- Resistance Level
- GENK $7.54
- LEXX $2.04
- Average True Range (ATR)
- GENK 0.33
- LEXX 0.22
- MACD
- GENK -0.02
- LEXX -0.02
- Stochastic Oscillator
- GENK 4.39
- LEXX 40.74
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.